Can GLP-1 weight loss drugs protect your brain as you age?

As weight loss medications attract growing interest for their potential effects on memory and brain health, researchers examine whether their neurological benefits could depend on who takes them and when treatment begins.

Review: Obesity pharmacotherapies and cognition. Image Credit: Corona Borealis Studio / Shutterstock

Review: Obesity pharmacotherapies and cognition. Image Credit: Corona Borealis Studio / Shutterstock

Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists, have changed how doctors treat obesity and type 2 diabetes, and attention is now turning to their effects on memory and cognition. In a recent review published in the journal Science, a team of researchers examined how current obesity medications may affect cognitive outcomes.

The research was led by scientists from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen in Denmark, in collaboration with researchers from the University of Gothenburg and Sahlgrenska University Hospital in Sweden, University College London in the United Kingdom, the University of Wisconsin in the United States, and the Indian Institute of Science in India.

Introduction

Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, act on hormone pathways to produce substantial weight loss and improve cardiometabolic health in people with obesity or type 2 diabetes (T2D).

Blood vessel dysfunction, obesity, and T2D are linked to impaired cognitive function and a higher chance of dementia, possibly through insulin resistance and chronic inflammation. Large observational datasets suggest that people with T2D taking GLP-1 receptor agonists develop dementia less often. Yet randomized trials in Alzheimer's disease have not shown clear clinical benefit, though some biological markers have changed. Whether any cognitive effect arises from direct action on brain cells, better metabolic health, or both remains unclear.

About the review

To examine potential cognitive benefits of incretin-based therapies, the authors conducted a narrative review of animal studies, observational cohorts, genetic analyses, brain imaging studies, and human clinical trials. They concentrated on GLP-1-based medications and on newer therapies that target the amylin, glucagon, and GIP pathways.

The analysis covered obesity, T2D, aging, and Alzheimer’s disease, including the distribution of hormone receptors in the brain, laboratory findings on learning and memory, and whether the drugs reached those regions at meaningful concentrations. Cardiometabolic disorders are more commonly associated with deficits in attention, executive function, and processing speed, while episodic memory impairment is more prominent in Alzheimer's disease.

Clinical evidence included a meta-analysis of GLP-1 receptor agonist trials in people with T2D, a multiyear dulaglutide trial, observational studies from patient registries, and randomized trials in Alzheimer’s disease. The choice of comparison groups was an important consideration because people taking different diabetes drugs could differ in illness severity and other health factors.

Evidence for indirect effects on brain health came from large trials of semaglutide and tirzepatide assessing cardiovascular health, kidney function, and sleep apnea, along with studies of weight loss surgery and structured lifestyle programs. The review also covered the use of biomarkers to distinguish disease pathology, brain injury, and drug action.

The possibility of improving cognition in metabolically healthy people was explored through animal research and two ongoing human studies investigating whether semaglutide affects cognition independently of substantial weight loss.

Key findings

The review found that current obesity medicines alter biological processes tied to cognition, but no reliable cognitive benefits have been established across clinical settings. The most consistent evidence came from observational data, which linked GLP-1 receptor agonist use to lower rates of cognitive decline or dementia in people with T2D. Differences in diabetes severity, hypoglycemia exposure, and frailty between patient groups may partly explain these associations.

Randomized trials were less clear. A pooled analysis of five studies involving 7,732 adults with T2D found no clear improvements in overall cognitive performance. In the REWIND trial of dulaglutide, the exploratory cognitive outcome defined before the trial did not differ from placebo over a median follow-up of 5.4 years. A post hoc analysis adjusted for baseline cognitive scores suggested a lower risk of substantial cognitive impairment.

In Alzheimer’s disease, liraglutide did not meet its primary endpoint of preserving cerebral glucose metabolism in 204 participants with mild-to-moderate disease over 52 weeks. Secondary and exploratory findings suggested slower decline on a combined measure of cognitive performance and less brain volume loss. These findings require confirmation and were not accompanied by improvements in daily functioning or overall clinical status.

Two larger phase 3 trials of oral semaglutide (EVOKE and EVOKE+) enrolled 3,808 people with biomarker-confirmed mild cognitive impairment or mild Alzheimer's dementia and ran for 104 weeks. Semaglutide did not slow clinical decline or deterioration in daily function. Cerebrospinal fluid levels of phosphorylated tau and neurogranin decreased, indicating a biological response to treatment. These biomarker changes do not establish clinical efficacy or direct receptor engagement in the brain.

In animals, long-acting GLP-1 drugs preferentially reached selected brainstem and hypothalamic regions, while evidence of drug exposure in memory-associated regions such as the hippocampus or cortex was inconsistent. Neural signals from accessible brain regions could still influence cognitive networks.

Evidence on the cognitive effects of therapies targeting GIP, amylin, and glucagon remains limited. Animal studies suggest possible effects on learning, memory, and neuroprotection, but whether these therapies offer cognitive benefits beyond GLP-1 receptor activation remains unknown. Chronically elevated levels of naturally occurring amylin have been linked to memory decline, while some synthetic, nonaggregating forms of amylin have improved memory in animal studies.

Semaglutide lowered the risk of major cardiovascular events in the SELECT trial and the combined risk of major kidney outcomes and cardiovascular death in the FLOW trial. Tirzepatide also reduced obstructive sleep apnea severity. These improvements could indirectly support brain health, but the trials did not establish cognitive benefits.

The authors noted that most mechanistic work came from animals and that smaller trials were generally short and underpowered. Body weight often fell as blood sugar control and sleep improved, making it difficult to determine which physiological changes, if any, contributed to cognitive outcomes. Rapid weight loss, muscle loss, inadequate nutrient intake, and dehydration could also offset potential cognitive benefits, particularly in older or frail individuals.

Conclusion

The review concluded that reducing dementia risk before symptoms develop may differ substantially from treating established Alzheimer's disease, where neuronal loss and accumulated brain pathology may limit the benefits of improved metabolic health. Preserving cognitive function in metabolically vulnerable people appears to be a more realistic near-term goal than improving cognitive performance in healthy individuals.

The authors called for future trials that measure specific cognitive abilities over time and track drug exposure and receptor engagement in the brain. New brain-penetrating peptides, small-molecule agonists, and targeted drug conjugates could help determine whether direct action on specific brain receptors is necessary to improve cognitive function.

The review received funding from several research organizations, including the Novo Nordisk Foundation. Coauthor Christoffer Clemmensen disclosed part-time employment with Novo Nordisk and interests in biotechnology companies and patents. Henrik Zetterberg also reported commercial relationships with pharmaceutical companies, including Novo Nordisk.

Source:

Journal reference:
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2026, November 18). Can GLP-1 weight loss drugs protect your brain as you age?. News-Medical. Retrieved on November 18, 2026 from https://www.news-medical.net/news/20261118/Can-GLP-1-weight-loss-drugs-protect-your-brain-as-you-age.aspx.

  • MLA

    Sidharthan, Chinta. "Can GLP-1 weight loss drugs protect your brain as you age?". News-Medical. 18 November 2026. <https://www.news-medical.net/news/20261118/Can-GLP-1-weight-loss-drugs-protect-your-brain-as-you-age.aspx>.

  • Chicago

    Sidharthan, Chinta. "Can GLP-1 weight loss drugs protect your brain as you age?". News-Medical. https://www.news-medical.net/news/20261118/Can-GLP-1-weight-loss-drugs-protect-your-brain-as-you-age.aspx. (accessed November 18, 2026).

  • Harvard

    Sidharthan, Chinta. 2026. Can GLP-1 weight loss drugs protect your brain as you age?. News-Medical, viewed 18 November 2026, https://www.news-medical.net/news/20261118/Can-GLP-1-weight-loss-drugs-protect-your-brain-as-you-age.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Brain-computer interfaces restore communication for people with paralysis